Clinical Trials Browser

Interventional × Pancreatic Neoplasms × olaparib × Clear all

NCT04548752 2026-05-13

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05411094 2026-05-13

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

Phase 1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT06545942 2026-04-17

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Active not recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04005690 2026-02-27

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Phase EARLY_PHASE1 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04753879 2025-12-04

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05252390 2025-11-06

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT05093231 2025-09-18

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06065059 2024-08-13

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Phase 1/2 Terminated

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT06078787 2024-05-06

PALBOLA

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT02184195 2023-09-13

POLO

Phase 3 Completed

154 enrolled 20 charts 1 FDA

Gastrointestinal

Pancreatic Neoplasms

NCT02511223 2023-04-19

10

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Phase 1 Completed

BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT01296763 2016-03-22

Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic Cancer

Phase 1 Completed

18 enrolled 12 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00515866 2013-12-20

Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms